Apri index changes after 4 weeks treatment of pentoxyfylline in chronic hepatitis B  

Oleh:

Zain, Lukman Hakim ; Zulfan

Jenis: Article from Journal - ilmiah nasional - tidak terakreditasi DIKTI
Dalam koleksi: Jurnal Kedokteran YARSI vol. 16 no. 02 (May 2008), page 83-86.
Topik: Liver Fibrosis; Hepatic Stellate Cell; Pentoxifylline; APRI Index

Ketersediaan

Perpustakaan PKPM Nomor Panggil: J51 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada	Lihat Detail Induk
Perpustakaan FK Nomor Panggil: J26.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada	Lihat Detail Induk

Isi artikel

Nowadays studies have shown that liver fibrosis is a reversible process. Theraupetic target on hepatic stellate cell (HSC) through inhibition of fibrotic signaling transduction is one of the way to treat liver fibrosis (e.g. pentoxifylline). APRI index, one of the indirect marker of liver fibrosis, had shown significant correlation (Spearman correlation y=0.7) with liver fibrosis degree in hepatitis B and C. This study was aimed to evaluated the effect of pentoxifylline treatment in 4 weeks for liver fibrosis measured by APRI index.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali